Reports Q1 revenue $22,000, consensus $10,000. “We are very proud of the progress we’ve made across our portfolio, in particular the transformative potential of our pivotal ALPHA3 trial with cema-cel which is expected to readout in 2026. Securing the EU and UK rights reinforces our conviction in the cema-cel program,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “We will continue to focus all of our resources on advancing these core programs and believe we are well-positioned to change the CAR T treatment landscape for the benefit of patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
- ALLO Upcoming Earnings Report: What to Expect?
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
- Allogene awarded $15M grant from CIRM to support ALLO-316 development
- IO Biotech appoints Shamsaei as SVP, Commercial Development